Puration Acquires 25 Greenhouse Grow Operation Entering $20 Billion Marijuana Market Opportunity
July 20 2017 - 9:00AM
InvestorsHub NewsWire
Dallas, TX – July 20, 2017
-- InvestorsHub NewsWire – Puration, Inc. (USOTC:
PURA) today announced the acquisition of a 25-greenhouse
grow operation. PURA operates a U.S. Patented Cannabis
Extraction process and sells its extracts for infusion into a
variety of consumer products to include beverages, foods,
nutritional supplements and cosmetics. The grow operation
will provide PURA the opportunity to refine its own strains of
cannabis to further enhance the efficacy of its extracts. The
Company recently announced a $1.2 million sales
contract executed in anticipation of the acquisition
announced today. The grow operation has the potential to
expand production to another 400 irrigated greenhouse pads ready
for buildout. Management anticipates the operations have the
potential to expand to as high as $16 million in annual
sales in the not too distant future, and substantially
higher to well over $100 million in annual sales
as the legalization process for medical marijuana matures. Forbes
reported that marijuana sales in the U.S. last year were over
$6 billion, and that marijuana sales in the U.S
are anticipated to exceed $20 billion by 2021.
Look for an online presentation from the Company next week about
the overall strategy behind the acquisition to include more insight
on the timing of the opportunity to reach $16 million in annual
sales and beyond.
Learn More About PURA:
purationinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies’ contracts, the companies’ liquidity position, the
companies’ ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure or prevent any disease.
Puration Contact:
Brian Shibley, CEO
info@purationinc.com
+1-214-937-9097
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Oct 2023 to Oct 2024